In these studies, authors demonstrated that the combined ipilimumab and nivolumab therapies had high response rates with more lymphoid infiltration, whereas treatment with nivolumab monotherapy had modest responses with a more clonal and diverse T cell infiltration in responders, respectively, and that low RNA expression of the IFN-γ signature was associated with relapse after combinational therapies (ipilimumab + nivolumab), while none of the patients with a high or intermediate IFN-γ signature has relapsed in high-risk melanoma patients (47). Here, IFNG is linked to melanoma.